Novartis heart drug fails trial, curbing growth prospects

Novartis's heart failure drug Entresto failed a trial in a new use, the Swiss drugmaker said on Monday, calling into question billions of dollars in potential revenue and taking the shine off one of the company's biggest growth prospects.